NYSE · BDX
Healthcare · Medical - Instruments & Supplies
$185.92
Up+$3.01 (+1.65%)
Updated Sep 16, 2026, 10:59 AM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BDX closed at $185.92 after 20 trading sessions, up 2.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $182.39 | $186.63 | $181.28 | $185.92 | 2.09M |
| Sep 14, 2026 | $180.05 | $183.53 | $179.60 | $182.91 | 1.63M |
| Sep 11, 2026 | $177.60 | $178.30 | $175.20 | $177.85 | 1.58M |
| Sep 10, 2026 | $178.94 | $178.94 | $175.67 | $176.42 | 1.71M |
| Sep 9, 2026 | $177.15 | $182.10 | $176.55 | $179.80 | 1.53M |
| Sep 8, 2026 | $181.75 | $182.20 | $178.47 | $179.10 | 1.81M |
| Sep 4, 2026 | $185.42 | $187.13 | $184.05 | $184.74 | 1.44M |
| Sep 3, 2026 | $188.97 | $189.47 | $184.91 | $187.62 | 1.21M |
| Sep 2, 2026 | $187.43 | $191.755 | $187.43 | $187.52 | 1.47M |
| Sep 1, 2026 | $190.30 | $191.57 | $186.48 | $187.12 | 1.28M |
| Aug 31, 2026 | $187.88 | $188.97 | $186.62 | $188.11 | 2.63M |
| Aug 28, 2026 | $188.04 | $190.32 | $187.5375 | $189.52 | 1.69M |
| Aug 27, 2026 | $189.29 | $190.41 | $187.73 | $188.13 | 1.35M |
| Aug 26, 2026 | $188.49 | $191.52 | $188.02 | $190.21 | 1.4M |
| Aug 25, 2026 | $189.31 | $190.07 | $187.03 | $189.78 | 1.21M |
| Aug 24, 2026 | $191.73 | $193.07 | $190.35 | $190.74 | 1.31M |
| Aug 21, 2026 | $188.02 | $192.295 | $186.95 | $192.00 | 2.52M |
| Aug 20, 2026 | $186.20 | $190.01 | $185.36 | $187.62 | 1.97M |
| Aug 19, 2026 | $183.71 | $187.96 | $181.5158 | $187.60 | 2.16M |
| Aug 18, 2026 | $184.94 | $185.80 | $180.72 | $180.77 | 1.62M |
The latest Smart Investors Daily articles mentioning BDX.
BDX research
Company profile and research snapshot.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 31, 2026 | B of A Securities | Neutral | — |
| Aug 13, 2026 | RBC Capital | Sector Perform | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
| Aug 7, 2026 | RBC Capital | Sector Perform | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Becton, Dickinson and Company (BDX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsThomas Polen - President,...
Yahoo · Sep 9, 2026
Becton Dickinson & Co (NYSE:BDX) recently announced a total dividend of $1.05 per share, with the ex-dividend date set for 2026-09-09. This cash dividend is payable on 2026-09-30. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.
Yahoo · Sep 4, 2026
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
Yahoo · Sep 4, 2026
Becton, Dickinson and Company has notably outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDX.
